medigraphic.com

2019, Number S1

<< Back Next >>

Cir Cir 2019; 87 (S1)

Eruptive palmoplantar lesions induced by capecitabine: report of a case evaluated with dermoscopy

García-Lozano JA, Ocampo-Candiani J, González-Ramírez RA

Language: Spanish
References: 30
Page: 38-42
PDF size: 226.49 Kb.


ABSTRACT

Capecitabine is a prodrug used primarily as a chemotherapeutic agent. Despite its good tolerance, it has several adverse effects, including the appearance of eruptive nevi. We present the case of a patient, with a history of EC IV breast adenocarcinoma and superficial extension melanoma, which developed 2 weeks after the start of therapy with capecitabine multiple eruptive palmoplantar pigmented lesions, with diverse benign dermatoscopic patterns. With the increasing incidence of solid tumors, these agents are being more used. It is important that the treating physician knows its adverse effects and apply non-invasive diagnostic tools like dermoscopy to avoid unnecessary biopsies.


REFERENCES

  1. Fortina AB, Piaserico S, Zattra E. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn’s disease. Melanoma Research. 2005;15(3):223-224.

  2. Hughes BR, Cunliffe W, Bailey C. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ. 1989;299(6691):88-91.

  3. Fukushima S, Hatta N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Brit J Dermatol. 2004;151(3):698-700.

  4. Bovenschen HJ, Tjioe M, Vermaat H. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Brit J Dermatol. 2006;154(5):880-884.

  5. Barker J, MacDonald D. Eruptive dysplastic naevi following renal transplantation. Clin Exper Dermatol. 1988;13(2):123-125.

  6. Hueso L, Requena C, Serra-Guillén C. Nevos plantares múltiples posquimioterapia. Actas Dermo-sifiliográficas. 2006;97(5):327-329.

  7. Duvic M, Lowe L, Rapini RP. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Archiv Dermatol. 1989;125(3):397-401.

  8. Villalon G, Martin JM, Pinazo MI. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. Am J Clin Dermatol. 2009;10(4):261-263.

  9. Vázquez-Bayo C, Rodríguez-Bujaldón A, Jiménez-Puya R. Capecitabine induced hyperpigmentation. Actas Dermo-Sifiliográficas (English edition). 2007;98(7):491-493.

  10. Kaklamani VG, Gradishar WJ. Role of capecitabine (Xeloda) in breast cancer. Expert Rev Antican Ther. 2003;3(2):137-144.

  11. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Seminars in oncology. 2003;30(2 Suppl 3):6-10.

  12. Dooley M, Goa KL. Capecitabine. Drugs. 1999;58(1) 69-76; discussion 77-68.

  13. Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Inter J Dermatol. 1995;34(3):219-220.

  14. Vukelja SJ, Bonner MW, McCollough M. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol. 1991;25(5 Pt 2):905-908.

  15. Maino KL, Norwood C, Stashower ME. Onycholysis with the appearance of a “sunset” secondary to capecitabine. Cutis. 2003;72(3):234-236.

  16. Chen GY, Chen YH, Hsu MM. Onychomadesis and onycholysis associated with capecitabine. Brit J Dermatol. 2001;145(3):521-522.

  17. Perry BM, Nguyen A, Desmond BL. Eruptive nevi associated with medications (ENAMs). J Am Acad Dermatol. 2016;75(5):1045-1052.

  18. Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol. 2005;52(5):S96-S100.

  19. Ross AL, Sánchez MI, Grichnik JM. Nevogenesis: a benign metastatic process? ISRN Dermatology. 2011;2011:813513.

  20. Holly EA, Kelly JW, Shpall SN. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17(3):459-468.

  21. Green A, MacLennan R, Siskind V. Common acquired naevi and the risk of malignant melanoma. Inter J Cancer. 1985;35(3):297-300.

  22. Bataille V, Bishop JA, Sasieni P. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Brit J Cancer. 1996;73(12):1605-1611.

  23. Halpern AC, Guerry Dt, Elder DE. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Archiv Dermatol. 1991;127(7):995-999.

  24. Allen AC. A reorientation on the histogenesis and clinical significance of cutaneous nevi and melanomas. Cancer. 1949;2(1):28-56.

  25. Pack GT, Lenson N, Gerber DM. Regional distribution of moles and melanomas. AMA Archiv Surgery. 1952;65(6):862-870.

  26. Zalaudek I, Catricala C, Moscarella E. What dermoscopy tells us about nevogenesis. J Dermatol. 2011;38(1):16-24.

  27. Woltsche N, Schwab C, Deinlein T. Dermoscopy in the era of dermato- oncology: from bed to bench side and retour. Exp Rev Antican Ther. 2016;16(5) 531-541.

  28. Phan A, Dalle S, Touzet S. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Brit J Dermatol. 2010;162(4):765-771.

  29. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011;38(1):25-34.

  30. González-Ramírez RA, Garza-Rodríguez V, Garza-Báez P, Gómez-Flores M, Ocampo-Candiani J. Dermoscopic features of acral melanocytic nevi in a case series from Mexico. An Bras Dermatol. 2018; 93(6):665-670.




2020     |     www.medigraphic.com